Adeno-Associated Virus Vector Service

Creative BioMart Vir-Sci is one of the well-recognized experts who is professional in Adeno-associated virus (AAV) vector service. We have years of AAV vector experience and advanced production systems and equipment to provide fast and satisfactory AAV vector service according to customer needs.

Adeno-Associated Virus

AAV is a type of single-stranded DNA-deficient virus with a simple structure and no envelope. It has the ability to infect cells that divide or not divide. Recombinant adeno-associated virus (rAAV) vector is derived from non-pathogenic wild-type AAV. Due to its good safety, a wide range of host cells (dividing and non-dividing cells), and low immunogenicity, it can express foreign genes in vivo. These features make rAAV a very attractive tool vector for gene transfer and gene therapy. To date, many clinical trials have used AAV vectors for gene therapy, including CFTR, Hemophilia B, arthritis, and Parkinson's diseases. Both phase I and phase II clinical trials have achieved ideal results.

Figure 1. Recombinant AAV features.

Our Services

• Production, Purification and Titration

For our recombinant AAV production, the transfer plasmid carrying the gene of interest (GOI) is co-transfected with our proprietary Rep-cap plasmid and auxiliary plasmids encoding adenovirus genes (E4, E2A and VA), which mediate AAV copy into packaging cells. After a short incubation, virus particles were harvested from cell lysates and concentrated by PEG precipitation. For ultra-purified AAV (in vivo grade), virus particles can be further purified and concentrated by gradient ultracentrifugation of cesium chloride (CsCl). We use qPCR-based methods to measure AAV titers.

• Quality Control

For each AAV, quality control includes titer measurement, sterility testing of bacteria and fungi, and mycoplasma testing. If the transfer vector encodes a fluorescent protein, we will transduce the cells with the virus and detect the corresponding fluorescence. In addition, for ultra-purified AAV, we usually sample the virus quality by SDS-PAGE analysis and endotoxin determination.

Our Advantage

• All vectors. Nearly 30 kinds of tissue-specific promoters (neural-specific promoters Human Synapsin, CamkIIα, GFAP, etc.) and multiple reporter genes (EGFP, mCherry, RFP, luciferase, etc.) are available for customers to choose.
• Short delivery time. AAV cloning vectors are common to our 18,000 prefabricated human full-length cDNA ORF cloning vectors in the MCS region, and the production cycle is short in the industry.
• High titer. Provide viruses with a titer of 10¹²V.G/ml and above. It can reach 10¹⁴V.G/ml.
• Multiple serotypes. AAV1, AAV2, AAV5, AAV6, AAV7, AAV8 and AAV9 ...
• High safety. ITR sequences and rep/cap genes are expressed by independent plasmids.
• Low immunogenicity. AAV2's genome is only 4681 nucleotides, which is convenient to operate with conventional recombinant DNA technology, and also for animal small immune response during the experiment.
• Stable expression. Mediate long-term stable expression of genes.

Applications

• AAV is commonly used in optogenetics experiments.
• AAV can insert genetic material into a specific site on chromosome 19 with close to 100% certainty
• These viruses are superior to lentiviruses

Workflow of Services at Creative BioMart Vir-Sci

Creative BioMart Vir-Sci has developed a professional AAV vector packaging service that can provide you with a small volume of virus stock solution and a large volume of customized purification products. Our product development platform can meet all your research and gene therapy needs. Creative BioMart Vir-Sci's powerful AAV vector production system makes AAV vector a very simple treatment method for a series of diseases. If you are seeking for related services, please feel free to contact us, our expert team will design high-quality virus production solutions according to your needs and provide you with professional and thoughtful services.

Reference

1. Kenneth Lundstrom., et al. Viral Vectors in Gene Therapy. Diseases, 2018, 6(2): 42.